UniProtKB/SwissProt variant VAR

Variant information

Variant position:

59

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

US

The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Arginine (R) to Cysteine (C) at position 59 (R59C, p.Arg59Cys).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Change from large size and basic (R) to medium size and polar (C)

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

-3

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Variant description:

In a prostate cancer cell line; somatic mutation.

Any additional useful information about the variant.

Other resources:

Links to websites of interest for the variant.

Variant rs121908982 [ dbSNP | Ensembl ]

Sequence information

Variant position:

59

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

718

The length of the canonical sequence.

Location on the sequence:

GSLQMQYQQSMQLEERAEQI R SKSHLIQVEREKMQMELSHK

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         GSLQMQYQQSMQLEERAEQIRSKSHLIQVEREKMQMELSHK

Mouse                         GSLQKQYEYHMQLEERAEQIRSKSYLIQVEREKMQMELSHK

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 718	Mitotic spindle assembly checkpoint protein MAD1
Coiled coil	46 – 632
Modified residue	61 – 61	N6-acetyllysine; alternate
Cross	61 – 61	Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate
Alternative sequence	1 – 65	MEDLGENTMVLSTLRSLNNFISQRVEGGSGLDISTSAPGSLQMQYQQSMQLEERAEQIRSKSHLI -> MLPARGCVRKRTVWPRLARVLIVTLLTLELSYAPLPCQLSGVPYNTGDPVGRWARPCIWPCPWHT. In isoform 2.
Alternative sequence	51 – 97	Missing. In isoform 3.
Mutagenesis	1 – 485	Missing. Defective dimerization. Abolishes binding to the closed and open conformations of MAD2L1. Impairs mitotic checkpoint signaling abolishing mitotic arrest, and shortens the duration of mitosis.

Literature citations

Mutations in the mitotic check point gene, MAD1L1, in human cancers.
Tsukasaki K.; Miller C.W.; Greenspun E.; Eshaghian S.; Kawabata H.; Fujimoto T.; Tomonaga M.; Sawyers C.; Said J.W.; Koeffler H.P.;
Oncogene 20:3301-3305(2001)
Cited for: VARIANTS CANCER LEU-29; CYS-59; GLN-360; LYS-516; CYS-556 AND LYS-569; VARIANTS MET-500 AND HIS-558;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9Y6D9: Variant p.Arg59Cys